Open AccessDetermination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity
Author(s) -
Maria M. Traczewski,
Jane E. Ambler,
Raymond Schuch
Publication year - 2021
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.03117-20
Subject(s) - broth microdilution , enterococcus faecalis , microbiology and biotechnology , staphylococcus aureus , clinical microbiology , antimicrobial , minimum inhibitory concentration , serial dilution , biology , bacteria , medicine , genetics , alternative medicine , pathology
Exebacase (CF-301), a novel, antistaphylococcal lysin (cell wall hydrolase) is the first agent of this class to enter late-stage clinical development (phase 3, NCT04160468) for the treatment ofStaphylococcus aureus bacteremia, including right-sided endocarditis. A multilaboratory Clinical and Laboratory Standards Institute (CLSI) M23-defined tier 2 quality control (QC) study was conducted to establish exebacase QC ranges for a new reference broth microdilution method.S. aureus ATCC 29213 andEnterococcus faecalis ATCC 29212 were selected as reference QC strains.